Ramón Salazar

The use of hormonal contraceptives is associated with a small increase in the risk of breast cancer—one additional case of cancer for every 7,752 women who use these drugs—according to a Swedish study. The risk varies depending on the type of hormones administered, and is slightly higher with the use of contraceptives containing desogestrel. The study, published in JAMA Oncology, analyses data from a national registry between 2006 and 2019, with more than two million women aged between 13 and 49.

For women diagnosed with early-stage breast cancer, the long-term risk of developing a second primary cancer is low, around 2–3 per cent higher than that of women in the general population. This is one of the conclusions of a study published by The BMJ, which analysed data from nearly half a million women diagnosed in England between 1993 and 2016 with early-stage invasive breast cancer who underwent surgery. During a follow-up period of up to 20 years, around 65,000 women developed a second primary cancer, but the absolute excess risk compared to the risks in the general population was small.

A team led by the Spanish National Cancer Research Centre (CNIO) has shown in mice that a high-fat diet increases metastasis in triple-negative breast cancer, which has the worst prognosis. In addition, it has identified several of the mechanisms that would explain this, such as the activation of platelets and coagulation, which would help the tumour hide from the body's defences and prepare the so-called ‘pre-metastatic niche’. According to the researchers, who published the results in Nature Communications, ‘this mechanism could be extrapolated to other tumour types and other organs’. The results suggest that ‘dietary intervention, together with the control of platelet activity, may increase the efficiency of certain anti-tumour treatments’.

An international team has found that aspirin is capable of reducing the appearance of metastasis in mice, by enabling the activation of T lymphocytes capable of recognising tumour cells. The research showed that several different mouse cancer models — including breast cancer, colon cancer and melanoma — treated with aspirin showed a lower rate of metastasis in other organs, such as the lungs and liver, compared to untreated mice. According to the authors, who publish the results in the journal Nature, ‘the finding paves the way for the use of more effective anti-metastatic immunotherapies’.

Research led by the Hospital del Mar Research Institute (Barcelona) and involving researchers from CIMA (University of Navarra) and Pompeu Fabra University (Barcelona) has revealed the existence of microproteins present almost exclusively in hepatocellular carcinoma, the most common form of liver cancer. These structures, which appear to be found in a significant percentage of patients, could be used to develop specific vaccines against this type of tumour. The results are published in the journal Science Advances.

The classical view describes most cancers as the result of mutations that happen by chance and accumulate over a lifetime. Now, a study claims to break that paradigm. A team of researchers from Stanford University (USA) has described that the genetics we inherit influences the surveillance that our defences do of these mutations, conditioning the type of tumour that can develop and its prognosis. The results, which for the moment refer to breast cancer, are published in the journal Science.  

A phase 2 clinical trial has tested a type of immunotherapy based on oncolytic viruses in combination with chemotherapy for the treatment of triple-negative breast tumours. The results are published in the journal Nature Medicine.